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care organization. Members initiating therapy between January
1, 2004 and June 30, 2004 with one of the following ﬁve AD
regimens were included in the analysis: donepezil, galantamine,
rivastigmine, memantine, or memantine+AChEI (acetyl-
cholinesterase inhibitor) combination. We excluded members
with previous AChEI use or who were not continuously enrolled
throughout the 360-day pre-treatment and 360-day post-treat-
ment initiation periods. Adherence was deﬁned as the total days
supplied (maximum of 360) of the AD medication initiated
divided by the total days in the post-period (360 days). Change
(post-treatment minus pre-treatment) in pharmacy, medical, and
total (pharmacy+medical) costs was analyzed, adjusting for age,
gender, comorbidities (chronic disease score), AD regimen, and
pre-treatment total costs. RESULTS: A total of 2405 members
were newly started on AD therapy; 65% were female and mean
age was 81 years (SD 7.1). Treatment was initiated with
donepezil (62%), memantine (15%), galantamine (11%),
rivastigmine (8%), and memantine+AChEI (6%). Mean adher-
ence to AD therapy was 0.57 (SD 0.36). The adjusted analysis
revealed that a 0.1 adherence rate increase (for example, an
increase in adherence from 0.5 to 0.6) was associated with an
increase of $215 (p < 0.001) in annual pharmacy costs and a
decrease of $783 (p < 0.001) and $568 (p = 0.008) in annual
medical and total health care costs, respectively. CONCLU-
SIONS: An increase in AD therapy adherence is associated with
overall health care cost savings in the ﬁrst year following 
treatment initiation.
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OBJECTIVES: To illustrate use of competing risk methodology
for studying risk of discontinuing, switching, or augmenting
medications used to treat bipolar disorders. METHODS: Admin-
istrative claims data (MarketScan®, Medstat) was used to iden-
tify patients with bipolar disorders treated with montherapy
atypical antipsychotics. Patients were followed 12 months to
identify those augmenting (starting second medication class
within 30 days and before any discontinuation), discontinuing
(medications runs out and no reﬁll within 30 days following
expiration of days supply), and switching (patient discontinues
medications and starts different class within 30 days). Because
risks of augmentation, discontinuation, and switching are not
independent, competing risk methods are used to summarize
likelihood of different outcomes. Cumulative incidence functions
are computed as a function of crude hazards for each of the 3
dependent outcomes. Plots of the cumulative incidence functions
provide estimates of the probability of each outcome occurr-
ing by any time point. RESULTS: A total of 787 patients on
monotherapy atypical antipsychotics were identiﬁed. By 6
months 21% of the patients had discontinued, 3% had switched,
56% had augmented, and the remaining 20% remained on their
initial antipsychotic. By one year 29% of the patients had dis-
continued, 4% had switched, 59% had augmented, and 8%
remained unchanged. CONCLUSIONS: Switching and augmen-
tation are outcomes important to study along with discontinua-
tion. Treating these as independent when estimating risk of each
(e.g. with complement of Kaplan-Meier estimates) would give
biased estimates of the marginal probabilities. Cumulative inci-
dence curves provide a means of dynamically seeing the risks of
all three outcomes.
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OBJECTIVE: Patients with Parkinson’s Disease (PD) have
diminished health related quality of life (HRQoL) due to a
number of emotional, functional and physical limitations. We
examined the reliability and validity of the PDQ-39 as both a
discriminant and evaluative instrument for use in Parkinson’s
disease studies. METHODS: We conducted a literature review
using MEDLINE and HealthStar citing the PDQ-39, from
1995–2005 using the terms “Parkinson’s Disease Questionnaire
or PDQ-39” limited to Humans and English language. We
reviewed each publication for evidence supporting the instru-
ment’s reliability face and content validity, construct validity
measured as the correlation of the PDQ-39 responses with other
relevant instruments and clinical measures, and test-retest relia-
bility or intra class correlation coefﬁcients. Discriminant abilities
were evaluated by looking for evidence of signiﬁcance between
PD patients with varying levels of disability. Responsiveness was
evaluated using change scores and established minimally impor-
tant difference (MID). RESULTS: Thirty-nine papers met the
inclusion criteria. Correlation of scales of the PDQ-39 with the
Medical Outcomes Study 36-item Short Form (SF-36) showed
strong correlation (>0.5). Intraclass correlation coefﬁcients for
each domain of the PDQ-39 ranged from 0.67 to 0.96 across
studies. Mean scores for each domain were shown to be signiﬁ-
cantly statistically different (p < 0.01) between PD patients with
Hoehn & Yahr rating I, II, III, and IV. Changes in PDQ-39 scores
were signiﬁcantly correlated with changes in patients’ retrospec-
tive judgments of change (0.25–0.31, p < 0.01), and changes on
the SF-36 (0.25–0.37, p < 0.05), but not with clinical assess-
ments. Two studies calculated a MID for the PDQ-39 which
varied between 5–10 points on the summary index and 2–11
points across domains. CONCLUSION: There is substantial evi-
dence supporting the reliability and validity of the PDQ-39 as a
discriminate instrument, but further research on its usefulness as
an evaluative instrument is warranted to increase our conﬁdence.
PNL30
COMPARISON OF HEALTH-RELATED QUALITY OF LIFE
QUESTIONNAIRES IN MULTIPLE SCLEROSIS: A REVIEW
Pawar VS, Miller LA
West Virginia University, Morgantown, WV, USA
Multiple sclerosis (MS) being a progressive neurological disease
with no cure, lends itself as an important area for health-related
quality of life (HRQOL) research. A number of questionnaires
have been designed to measure HRQOL in MS patients, but no
one measure has been established as a gold standard. The large
number of questionnaires also gives neurologists a range of
choices but limited information on which to base their selection.
In order to determine the relative advantages and disadvantages
of the HRQOL questionnaires, a comparison of their psycho-
metric properties in the same patient population is necessary.
OBJECTIVE: To review the current literature and identify
studies comparing psychometric properties of MS-related QOL
measures within the same patient population. METHODS:
Studies included were those that administered more than one
HRQOL questionnaire in the same group of patients with MS.
The search was restricted to the PUBMED and MEDLINE data-
bases for articles published between 1991 and 2005. RESULTS:
Of almost 30 MS-related QOL questionnaires, psychometric
